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AIM:  This study aims to determine what portion of specific autoantibody 
phenotypes are genetically determined by using a twin model.  METHODS:  This study 
specifically examines Anti-Ro(SSA), Anti-La (SSB), Anti-Sn/RNP, Anti-Sm, Anti-Jo-1, 
Anti-Scl-70, Anti-Tg & Anti-TPO, Anti-dsDNA, Anti-PS, and Anti-cardiolipin antibodies 
for their heritability.  This study examined 104 same-sex adult twins (66 monozygous, 38 
dizygous) for the above mentioned autoantibody values.  The serum autoantibody values in 
each subject were quantified using automated ELISA.  Descriptive statistics including, 
distributions, quantiles, and moments were calculated by zygosity for continuous antibody 
values, subject ages, gender, race and smoking status.  Categorical antibody levels were 
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used to determine twin pair concordance rates.  Continuous and rank ordered autoantibody 
values were used to determine the presence and portion of a genetic component.  To 
evaluate how strongly the antibody values in each twin group resembled each other, the 
intraclass correlation was calculated for each antibody by zygosity.  The genetic variances, 
environmental variances, and heritability were estimated using path models with maximum 
likelihood estimation techniques.  The phenotypic variance was modeled as a linear 
function of underlying additive genetic (A), dominant genetic (D), common environmental 
(C), and random environmental (E) effects.  RESULTS:  Several antibodies demonstrated 
a genetic component in our study population.  Anti-cardiolipin had a genetic component 
with an estimated 69% heritability.  Anti-dsDNA yielded a genetic component with a 
heritability estimate of 55-62%.  Anti-Jo-1 presented a genetic component with the 
heritability estimate to be 41-51%.  Anti-SCL-70 demonstrated a genetic component with a 
heritability estimate of 42-59%.  Anti-PL had a genetic component with a heritability 
estimate of 52-54%.  Several antibodies did not have a measurable genetic component.  
These included anti-Sm, anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO.  
Some possibilities for the lack of a measureable genetic component may be due to the 
limited number of discordant twin pairs and/or the small number of subjects with higher 
levels of antibodies.  CONCLUSION:  The results of this study suggest several clinically 
relevant markers of auto-immunity may be partially genetically determined. These include:  
anti-cardiolipin, anti-dsDNA, anti-Jo-1, anti-SCL-70, and anti-phospholid.   
  This document was created in Microsoft Word 2003 SP3. 
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CHAPTER 1 INTRODUCTION 
 
 
Autoimmunity is the failure of an organism to recognize its own constituent parts 
as self, which results in an immune response against its own cells and tissues.   Numerous 
diseases result from such an aberrant immune response.   Prominent examples include 
Celiac disease, diabetes mellitus type 1 (IDDM), systemic lupus erythematosus (SLE), 
Sjögren's syndrome, Churg-Strauss Syndrome, Hashimoto's thyroiditis, Graves' disease, 
idiopathic thrombocytopenic purpura, and rheumatoid arthritis.   
Most autoimmune diseases have evidence of a genetic and environmental 
component.  Studies have found familial aggregation of autoimmune diseases such as SLE 
and rheumatoid arthritis.  An analysis of a cohort of 1,177 SLE patients found an increased 
prevalence of SLE and rheumatoid arthritis in siblings1.  They also found an increased 
familial aggregation of autoimmune diseases in this SLE cohort.  Other diseases with 
evidence of a strong genetic component include autoimmune thyroid diseases.  Twin 
studies and familial aggregation indicate that autoimmune thyroid diseases have a complex 
genetic component.  These studies implicate major histocompatability complex and the 
single nucleotide polymorphism Fc receptor-like 3 as genetic factors2.   
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Some autoimmune diseases do not have strong evidence for a specific genetic 
component.  An example includes Sjögren's syndrome.  The prevalence of primary 
Sjögren's syndrome in siblings of affected individuals has been estimated to be 0.09% 
while the reported general prevalence of the disease is approximately 0.1%3.   However, 
there has been an observed aggregation of other autoimmune diseases in families of 
patients with Sjögren's syndrome.   
For the majority of these diseases and their specific markers, it is not clear what 
portion is heritable.  Understanding the genetic and environmental component of 
autoimmune markers is the first step in developing novel treatments for autoimmune 
diseases.  This study examines what portion of specific autoimmune markers are 
genetically determined by using a twin model.  The subject sample utilized in this study is 
an existing set of monozygous and dizygous twins with cross sectional assays of 
autoantibodies.  This unique population of twins was originally recruited as part of another 
study examining genetic risk for periodontal disease4.  The assays conducted included anti-
nuclear, anti-thyroid, and anti-phospholipid antibodies with diagnostic or clinical 
relevance.   
 
Anti-Nuclear antibodies 
Anti-Ro(SSA), Anti-La (SSB), Anti-Sn/RNP, Anti-Sm, Anti-dsDNA, Anti-Jo-1, Anti-Scl-70 
 
Several unique autoantibodies are associated with autoimmune diseases and are 
frequently used as serological markers for diagnosis and monitoring.  A common 
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serological indicator of autoimmunity in rheumatic disease is the Ro(SSA) antigen5. Over 
half of patients with Sjögren's syndrome (SS), one-third of patients with systemic lupus 
erythematosus (SLE), and 3-5% of patients with rheumatoid arthritis (RA) have antibodies 
to Ro(SSA).  Other diseases which have been associated with these antibodies include:  
Sjögren's syndrome-lupus overlap disease, subacute cutaneous lupus erythematosus, lupus 
with complement component deficiencies, neonatal lupus syndrome, multiple myeloma, 
polymyositis, progressive systemic sclerosis and primary biliary cirrhosis6.  Anti-Ro(SSA) 
antibodies are also found in healthy women of reproductive age with an incidence of 1%7, 
8. Anti-La(SSB) antibodies are typically found in conjunction with anti-Ro(SSA)9, 10.   
Small RNA molecules called hy-RNAs are the target protein antigens of anti-Ro(SSA)11. 
Complexes of the anti-RO(SSA) with hy-RNAs are termed Ro-ribonucleoproteins (Ro-
RNPs) exist but it is not yet clear what their biological function is12.  Both anti-Ro/SSA 
and anti-La/SSB antibodies are directed against extractable nuclear antigens.   
Another group of nuclear proteins, known as the Sm proteins, were first discovered 
as antigens targeted by anti-Sm antibodies in a patient with SLE.  Other proteins with very 
similar structures were subsequently discovered and named LSm proteins. New members 
of the LSm protein family continue to be identified and reported. The Sm autoantigens, 
named after patient Smith’s prototype serum, were isolated in the 1960’s by 
immunodiffusion13. As in the case with autoimmune syndrome, anti-Sm antibodies are 
often found concurrent with other autoantibodies, including, SSA(Ro), SSB(La), DNA, 
histone, and RNP.  Anti-Sm is, however, a highly specific marker for SLE since there is a 
25% prevalence of anti-Sm in SLE patients14.  
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Sm autoantigen is a class of antibodies against the group of nuclear Sm antigens.   
There are currently nine unique proteins which are classified as Sm antigens.  These nine 
polypeptides comprise the core proteins of small nuclear ribonucleoprotein (snRNP) 
particles.  The typical biological function of SnRNPs is involvement in pre-mRNA-
splicing15.  Anti-Sm antibodies bind to a broad variety of snRNAs16.  This is due to the fact 
that they interact with proteins common to different subunits of snRNP particles (B, D, E, 
F and G subunits).  The D subunit reacts to the majority of Sm autoantigen, however 
several of the subunits share at least one epitope.  An explanation for the immunologic 
cross-reactivity of Sm proteins is the evolutionarily conserved structural sequence motifs.  
Sequence comparison has shown that all of the known Sm proteins share two 
evolutionarily conserved structural sequence motifs17.  
The snRNP particles are also known to elicit an autoantibody response in certain 
individuals.  Anti-sn/RNP antibodies were first observed in SLE patients16.  Later, anti-
sn/RNP antibodies were also associated with mixed connective tissue disease (MCTD) 
patients.  Studies have found that high levels of anti-sn/RNP in the absence of Sm to be a 
reliable marker for MCTD18.   Anti-sn/RNP also occurs in other rheumatic diseases such as 
progressive systemic sclerosis, rheumatoid arthritis, discoid lupus erythematosus, Sjögren's 
syndrome, and overlapping conditions. 
Another potential antigenic component in the nucleus is DNA itself.  In some 
circumstances, double stranded DNA can create an autoimmune response.  Anti-double 
stranded DNA (Anti-dsDNA) is an IgG or IgM anti-double stranded DNA antibody that 
binds to nuclei or nuclear components.  Anti-dsDNA is associated with several conditions 
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including, systemic lupus erythematosus (SLE), rheumatoid arthritis, mixed connetictive 
tissue disease, Sjögren's syndrome, and necrotizing vasculitis.  Serum anti-dsDNA levels 
correlate with SLE disease activity and are highly specific to SLE19.  High levels are 
associated with kidney and blood vessel damage.   
The tRNA synthetase group of enzymes is another target for anti-nuclear 
antibodies.  The histidyl-tRNA synthetase (HRS) enzyme is the target for anti-Jo-1.  The 
HRS enzyme catalyses the following chemical reaction. 
 
ATP + L-histidine + tRNAHis AMP + diphosphate + L-histidyl-tRNAHis  
   
HRS specifically catalyses the coupling of L-histidine to tRNAHis before transport to the 
ribosome20.  At the ribosome, L-histidyl-tRNAHis is incorporated into a polypeptide chain 
during protein synthesis.  Anti-Jo-1 is the most common autoantibody in polymyositosis 
(PM) and dermatomyositis (DM)21.  PM and DM are inflammatory myopathies with 
proximal muscle weakness, and elevated muscle enzyme activities.  PM and DM patients 
have a reported an auto-antibody prevalence rate up to 89%, indicating a likely 
autoimmune pathology21.  The specific prevalence rate for anti-Jo-1 is 15-20% of 
myositosis patients and about 30% of adult PM patients22.   Anti-Jo-1 antibodies are 
capable of inhibiting HRS activity, may immunoprecipitate labeled enzyme, and may 
precipitate tRNAhis23. 
Another anti-nuclear antibody is the anti Scl-70.  The antigen of Anti Scl-70 was 
recognized as topoisomerase I in 198624.   Topoisomerase I assists in DNA reproduction, 
by cutting one strand of a DNA double helix, allowing relaxation, and subsequent 
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reannealing of the cut strand.  Topoisomerase I solves the problem caused by tension 
generated by the winding/unwinding of DNA25.  Anti Scl-70 is recognized as one of two 
major classes of autoantibodies in scleroderma.   Scleroderma, also known as progressive 
systemic sclerosis, is a chronic autoimmune disease characterized by a hardening or 
sclerosis in the skin or other organs26.  Scleroderma’s clinical manifestations include 
collagen deposition leading to connective tissue destruction of the skin, blood vessels, and 
some internal organs.  A study has estimated the prevalence of scleroderma to be 1 per 
500027.  The prevalence of anti-Scl-70 in scleroderma patients is approximately 25%28.  
Those scleroderma patients with more skin lesions tend to have the highest rates of Anti-
Scl-70 antibodies in their sera29.   
 
Anti-Thyroid antibodies 
Anti-Tg & Anti-TPO 
 
Detection of autoantibodies to the two major thyroid antigens thyroglobulin (Tg) 
and thyroid peroxidase (TPO) is valuable in the diagnosis of patients with thyroid disease. 
Over 98% of thyroiditis patients have autoantibodies directed to either or both of these 
antigens.  
The presence of anti-Tg autoantibodies has been shown to be a strong indicator of 
chronic autoimmune thyroid diseases such as Hoshimoto's thyroiditis and Graves disease30, 
31. While many patients elaborate antibodies to both thyroid antigens, several cases have 
been shown to be anti-Tg positive and anti-TPO negative, or vice versa. Therefore, 
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combined determination of both anti-Tg and anti-TPO antibodies provides the most 
accurate diagnostic tool for thyroid autoimmunity. 
 
Anti-Phospholipid antibodies 
Anti-PS & anti-cardiolipin 
 
Anti-phospholipid antibodies are antibodies against specific phospholipids found in 
cell membranes32.  Anti-phospholipid antibodies react against proteins that bind to anionic 
phospholipids on plasma membranes.  Anti-phospholipid antibodies are associated with 
primary and secondary antiphospholipid syndromes.  Primary antiphospholipid syndrome 
is a disorder of coagulation, that may cause thrombosis, miscarriage, preterm delivery, and 
severe pre-eclampsia.  Secondary antiphospholipid syndrome occurs with other auto-
immune diseases such as SLE.  Anti-phosphatidylserine antibody (Anti-PS) is a common 
antibody associated with both antiphospholipid syndromes33. 
A specific antiphosholipid antibody is anti-cardiolipin.  Cardiolipin is a 
mitochondrial membrane phospholipid.  Anti-cardiolipin is associated with 
antiphospholipid syndrome, livedoid vasculitis, myocardial infarction, Behçet's syndrome, 
SLE, rheumatoid arthritis, and scleroderma34-36.  Anti-cardiolipin has been associated with 
cardiovascular sequelae such as atherosclerosis and stroke37.  Anti-cardiolipin has been 
linked to adverse pregnancy outcomes such as idiopathic spontaneous abortion, fetal 
involution, prematurity, and low birth weight38.  Antibodies to cardiolipin require a co-
factor called -2-glycoprotein I for binding39.  -2-glycoprotein I is a phospholipid-
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binding protein that functions as a anticoagulant40. Studies suggest that bound -2-
glycoprotein I forms the antigen to which antibodies are directed.  It is also hypothesized 
that the anti-cardiolipin and -2-glycoprotein I complex may have several inhibitory 
effects on the coagulation pathway and platelet aggregation39.   
This study aims to determine what portion of specific autoantibody phenotypes are 
genetically determined by using a twin model.  This study specifically examines Anti-
Ro(SSA) antibodies, Anti-La (SSB) antibodies, Anti-Sn/RNP, Anti-Sm antibodies, Anti-
Jo-1 antibody, Anti-Scl-70 antibody, Anti-Tg & Anti-TPO antibodies, Anti-dsDNA 
antibody, Anti-PS antibodies, and Anti-cardiolipin antibodies for their heritability. 
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CHAPTER 2 METHODS 
 
 
Sample Population & Examination Protocol 
This cohort included one-hundred four (104) same-sex adult twin pairs that were 
originally part of a study examining periodontal disease and autoimmunity. The subjects 
were recruited from the Virginia twin registry.  The registry contained the names of over 
20,000 twins born in Virginia between 1915 and 1975.  Informed consent was obtained 
from all subjects with approval from the Virginia Commonwealth University’s 
Institutional Review Board.  The zygosity of all twins was classified using a biographical 
questionnaire designed to assess physical similarities during youth41.   
 
Assays of antibodies 
All subjects had one blood sample taken and processed for serum, which was then 
stored at -20°C until utilized.  Automated cross sectional enzyme linked immuno-sorbent 
assays (ELISA) of cotinine and autoantibodies were conducted on these serum samples.  
Serum samples were assayed by Dyn-BioShaf, LTD, Tel Hannan, Israel.  The antibodies 
assayed included the following: 
 
Anti-Ro(SSA) antibodies (IgG) 
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Anti-La SSB antibodies (IgG) 
Anti-Sn/RNP (IgG) 
Anti-Sm antibodies (IgG) 
Anti-Jo-1 antibody (IgG) 
Anti-Scl-70 antibody (IgG) 
Anti-Tg & Anti-TPO antibodies (IgG, IgM, IgA) 
Anti-dsDNA antibody (IgG) 
Anti-PS antibodies (IgG, IgM, IgA) 
Anti-cardiolipin antibody (IgG, IgM, IgA) 
 
Statistical Methods 
Descriptive statistics including distributions, quantiles, and moments were 
calculated by zygosity for continuous antibody values, subject ages, gender, race and 
smoking status.  The antibody data was categorized as high or low by comparing to 
standard curves established with 100 healthy subjects.  The categorical antibody data was 
used to calculate percent concordance for each twin pair.  Descriptive statistics and 
concordance were calculated using statistical analysis (JMP® Statistical Discovery 
Software Ver 8.0) and spreadsheet software (Microsoft Office Excel ® 2003).    
The one-way random effects model was used to calculate intraclass correlations 
with 95% confidence intervals for each antibody by zygosity.   Due to the distribution of 
the auto-antibody values, the values were adjusted by ranking from lowest to highest.  The 
ranked antibody values also had intraclass correlation coefficients calculated by zygosity.  
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Intraclass correlations adjusted by significant covariates were additionally determined.  
Significant covariates used for adjusting intraclass correlations were selected by using a 
multivariate step-wise regression technique.  Intraclass correlations were calculated using 
statistical analysis software (PASW Statistics Ver 17.0). 
In order to determine what portion of specific autoantibody phenotype is 
genetically determined, genetic variances, environmental variances, and heritability was 
estimated using path models with maximum likelihood estimation techniques.  The 
phenotypic variance was modeled as a linear function of underlying additive genetic (A), 
dominant genetic (D), common environmental (C), and random environmental (E) effects.  
Univariate path models coupled with maximum likelihood estimation coefficient models 
were used to estimate these parameters for each antibody.  Both antibody values and 
antibody rank values were analyzed using path modeling.  Variance/covariance matrices 
were used with the structural equation modeling methods contained in an on-line module 
(http://statgen.iop.kcl.ac.uk/bgim/twinfit.html) and with Windows Mx GUI (Version 1.54a, 
Virginia Commonwealth University, Richmond, Virginia) to estimate model parameters 
using maximum likelihood techniques.  The fit of the model was evaluated from log 
likelihood computations with an alpha of 0.05.  The full ADCE model could not be tested 
since D and C are confounded when data are available only from reared together twins.  
The fits of reduced models were compared to the full model (e.g., ACE or ADE) by 
inspecting changes in -2*log likelihood values relative to differences in the degrees of 
freedom between models42.  The module returned the maximum-likelihood estimates for 
the ACE, ADE, nested sub-models, determined the best-fitting, most parsimonious model, 
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and gave standardized estimates of the model parameters.  A statistically significant 
estimate of the A or D parameter signified the presence of significant broad sense 
heritability.  Broad sense heritability estimates for each antibody were calculated as the 
ratio of genetic variance to total variance.  
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CHAPTER 3 RESULTS 
 
 
This study examined a monozygous-dizygous twin population to evaluate the 
heritability of eleven autoantibodies.  Autoantibodies were measured once in the serum of 
the study population.  The level of autoantibodies was quantified using ELISA.  The 
distribution of each of the eleven antibodies proved to be skewed (Table 1).  The majority 
of subjects tended to have minimal values and a few subjects exhibited higher values, 
however, there were not enough subjects with higher values to show a true bimodal 
distribution.  The autoantibody values were examined three ways, categorically, 
continuously, and by ranking the continuous values.  The categorical antibody values were 
used to determine concordance rates between twin pairs.  The continuous and ranked 
antibody values were examined using intraclass correlations and ADCE path modeling.  
These multiple analysis methods were chosen in order to correct for the skewed 
distributions and to thoroughly evaluate the antibody values for evidence of heritability.   
Descriptive statistics are shown in Table 1.  Monozygous and dizygous groups 
were evaluated for statistically significant differences at an α < 0.05 with χ2 testing on 
gender, smoking, and racial data.  Student’s t test (α < 0.05) was used to evaluate 
statistically significant differences for age and autoantibody values.  The monozygous 
(n=66) and dizygous (n=38) twins were statistically similar in age and percent of smokers.  
The mean ages were 44 and 47 years for the monozygous and dizyogous twins 
respectively.  The percentage of current smokers was 30% for the monozygous group and 
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26% for the dizygous group.  The monozygous twins were more likely to be African 
American and female, however, these differences were not statistically significant.  There 
were 20% more females and 8% more African Americans in the monozygous group.  The 
mean values, standard deviation, minimum, maximum, and median for each autoantibody 
are presented in Table 1.  The autoantibody means were not significantly different between 
the monozygous and dizygous groups. 
Categorical analysis provided a method to compare the subjects with higher values 
to those with lower values.  The antibody values were categorized as high or low by 
comparison to standard curves.  The categorized values were used to determine 
concordance between twin pairs (Figure 1).  The monzygous twin pair concordance was 
compared to the dizygous twin pair concordance for each of the 11 antibodies.  There were 
no significant differences between the concordance of monzygous versus dizygous twin 
pairs for any of the 11 antibodies evaluated.  The categorical method minimizes variance in 
the data, but at a cost of statistical power.  There were not enough subjects to detect a 
significant difference in categorical conocordance rates.  Categorizing the auto-antibody 
values as high or low is also dependent on the cut-off point selected for high values.   
In order to determine how strongly the antibody values in each twin group 
resembled each other, the intraclass correlation coefficients were calculated.  The intraclass 
correlation coefficients and 95% confidence intervals are presented in Table 2 for each 
antibody by twin group.   To provide the greatest power to detect evidence of heritability, 
the continuous autoantibody values were examined.   Higher correlation coefficients 
represent greater similarities within the twin group.  The intraclass correlation coefficients 
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were compared between the monzygous and dizygous twin groups to determine evidence 
of a genetic effect.  If there is a significant genetic component to an autoantibody value, 
one would expect the monozygous intraclass correlation coefficient to be greater than that 
of the dizygous group.  Anti-SCL-70 and anti-PS antibodies had significant differences (α 
< 0.05) in their intraclass correlation coefficients between the monozygous and dizygous 
groups.  Both anti-SCL-70 and anti-PS antibodies had a greater intraclass correlation 
coefficient in the monozygous group.  Examining intraclass-correlation in the continuous 
data of our study population finds anti-SCL-70 and anti-PS antibodies to potentially have a 
genetic component.   Table 2 includes both the unadjusted and adjusted intraclass 
correlation coefficients.  Smoking status, race, gender, and age were evaluated for 
significant confounding using stepwise regression.  Race, gender, and age did not prove to 
be significant confounders for any antibody.  Only anti-cardiolipin and anti-SCL-70 values 
were significantly related to smoking.     
The options to examine data that has a skewed distribution include categorizing, 
excluding outliers, adjustment (i.e. logarithmic or exponential), or ranking.  A decision was 
made to rank the antibody values in order to maintain the full distribution of the data but 
minimizing the range and variance.  Antibody values were ranked from the lowest to 
highest for each twin group.  The intraclass correlation was calculated for each antibody 
(Table 3). The intraclass correlation coefficients and 95% confidence intervals are 
presented in Table 3 for each antibody by twin group.  Table 3 includes both the 
unadjusted and adjusted intraclass correlation coefficients.  Smoking status, race, gender, 
and age were evaluated for significant confounding using stepwise regression.  Race, 
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gender, and age did not prove to be significant confounders for any antibody.  As with the 
non-ranked values, only anti-cardiolipin and anti-SCL-70 values were confounded by 
smoking.  Also similar to the non- ranked values, only anti-SCL-70 and Anti-PS antibodies 
had significant differences (α < 0.05) in their intraclass correlation coefficients between the 
monozygous and dizygous groups.  Both anti-SCL-70 and anti-PS antibodies had a greater 
intraclass correlation coefficient in the monozygous group.  All intraclass correlation 
coefficients were equal to or greater than those found using continuous autoantibody 
values.  This was to be expected, since the ranked values were more closely correlated than 
the continuous values.  Examining intraclass correlation in the ranked data of our study 
population found anti-cardiolipin, anti-dsDNA, anti-SCL-70, and anti-PS antibodies to 
potentially have a genetic component.  When both the continuous and ranked intraclass 
correlation were taken into consideration, anti-SCL-70 and anti-PS antibodies were the 
most likely to have a genetic component. 
In order to determine what portion of specific autoantibody phenotype is 
genetically determined, genetic and environmental variances, and heritability were 
estimated using path models with maximum likelihood estimation techniques.  Path 
models coupled with maximum likelihood estimation methods have an advantage over 
conventional ANOVA methods in that the fit of full and reduced models can be evaluated 
and compared using the data43.  There are several basic assumptions of path model fitting 
to twin data.  The variances in the monzygous and dizygous groups must be approximately 
equal.  If they are not, a poor fit or a failure of convergence will result42.  The covariances 
must be less than the variances, which is a basic property of all properly-constructed 
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covariance matrices.  The dizygous covariance must be less than the MZ covariance which 
is an implication of the genetic model.  The ACE model will never fit well if this is not 
true, although it is possible to observe this given the nature of random sampling.  Some 
antibodies violated the basic assumptions of the path model, and were noted as non-
convergent.     
The results of the convergent path models using continuous antibody values are 
shown in Table 4.  Table 4 presents the most parsimonious model and parameter estimates 
for each antibody.  The most parsimonious model for anti-cardiolipin as well as anti-TPO 
was CE, indicating no genetic component.  The most parsimonious model for anti-dsDNA 
and anti-SCL-70 was AE, indicating an additive genetic component.  The most 
parsimonious model for anti-Jo-1 and anti-PS was DE, indicating a dominant genetic 
component.   
The ratio of genetic variance to total variance (broad sense heritability) was 
calculated from the path models and presented in Table 5.  The broad sense heritability is 
more meaningful then the narrow sense additive or dominant genetic effects, since the 
power was insufficient to distinguish between broad sense and narrow sense heritability.  
Table 5 lists the heritability estimates for the most parsimonious model, the full ACE 
model, and the full ADE models.  The heritability estimate was 55% for anti-dsDNA, 41% 
for anti-Jo-1, 42% for anti-SCL-70, and 52% for anti-PS.   
Heritability was estimated using path models on the ranked antibody data as well.  
The results of the convergent path models using antibody value ranking are shown in Table 
6.  Table 6 presents the most parsimonious model and parameter estimates for each 
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antibody.  The most parsimonious model for anti-Sm, anti-Ro(SSA), and anti-n-RNP was 
CE, indicating no genetic component.  The most parsimonious model for anti-cardiolipin, 
anti-dsDNA, anti-Jo-1, and anti-SCL-70 was AE, indicating an additive genetic 
component.  The most parsimonious model for anti-PS was DE, indicating a dominant 
genetic component.   
Table 7 lists the heritability estimates using the ranked antibody values for the most 
parsimonious model, the full ACE model, and the full ADE models.  The heritability 
estimate was 69% for anti-cardiolipin, 62% for anti-dsDNA, 51% for anti-Jo-1, 59% for 
anti-SCL-70, and 54% for anti-PS.  
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TABLE 1  Descriptive Statistics
MZ (n=66) DZ (n=38)
Mean SD Minimum Maximum Median Mean SD Minimum Maximum Median
Age (years) 43.7 3.9 39.1 52.9 42.5 46.6 4.5 38.7 55.3 47.0
Cardiolipin 18.7 25.8 0.0 156.5 9.8 13.6 12.1 0.4 51.2 9.3
dsDNA 28.3 28.6 2.5 176.8 21.6 26.6 18.3 4.4 87.4 22.5
Jo-1 10.9 11.3 2.3 73.6 7.2 9.3 9.5 1.9 60.4 6.9
Sm 17.7 18.6 1.7 87.6 11.9 13.2 14.2 0.6 84.9 10.2
Ro(SSA) 33.0 149.0 1.3 1209.0 7.6 15.5 16.6 0.7 59.0 5.1
La(SSB) 20.4 78.6 1.2 642.4 6.2 10.1 18.1 0.9 107.4 5.1
Sn/RNP 16.4 32.7 0.7 255.7 8.1 8.7 9.1 0.5 37.4 4.5
SCL-70 9.5 9.3 2.2 55.8 6.3 8.2 6.2 1.8 23.9 5.5
PS 17.9 14.2 0.7 69.8 14.2 20.3 18.7 2.8 86.7 15.1
Tg 25.4 20.9 10.2 151.6 19.0 32.7 32.6 8.6 198.3 22.6
TPO 24.9 76.0 1.0 517.4 3.3 33.9 93.9 1.1 416.5 4.5
Number % Number %
Female 50 67% 18 47%
Current Smokers 20 30% 10 26%
African American 16 24% 6 16%
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TABLE 2  Intraclass Correlation Coefficients
ICC (95% CI)
antibody MZ lower bound upper bound DZ lower bound upper bound adjusted for
Cardiolipin 0.663 0.422 0.818 0.562 0.167 0.804 -
dsDNA 0.495 0.191 0.713 0.413 -0.028 0.722 -
Jo-1 0.424 0.103 0.666 -0.002 -0.438 0.439 -
Sm 0.321 -0.016 0.594 0.519 0.107 0.781 -
Ro(SSA) 0.004 -0.332 0.341 0.105 -0.347 0.522 -
La(SSB) -0.015 -0.349 0.324 0.046 -0.398 0.477 -
Sn/RNP 0.144 -0.202 0.459 0.368 -0.081 0.696 -
SCL-70 0.312 -0.026 0.587 0.251 -0.208 0.623 -
PS 0.535 0.243 0.739 0.002 -0.434 0.443 -
Tg -0.038 -0.368 0.303 -0.002 -0.438 0.439 -
TPO 0.611 0.347 0.786 0.555 0.157 0.800 -
Cardiolipin 0.660 0.426 0.805 0.671 0.257 0.844 smoking
SCL-70 0.294 -0.014 0.558 -0.328 -0.688 0.114 smoking  
TABLE 3  Intraclass Correlation Coefficients for Ranked Autoantibody Values
ICC (95% CI)
antibody MZ lower bound upper bound DZ lower bound upper bound adjusted for
Cardiolipin 0.688 0.458 0.832 0.409 -0.032 0.720 -
dsDNA 0.608 0.342 0.784 0.371 -0.078 0.698 -
Jo-1 0.505 0.204 0.719 0.324 -0.130 0.669 -
Sm 0.676 0.440 0.825 0.594 0.214 0.820 -
Ro(SSA) 0.458 0.144 0.689 0.443 0.009 0.739 -
La(SSB) 0.390 0.063 0.643 0.456 0.026 0.747 -
SnRNP 0.714 0.498 0.847 0.657 0.310 0.851 -
SCL-70 0.566 0.285 0.759 0.341 -0.112 0.679 -
PS 0.546 0.258 0.746 0.047 -0.397 0.478 -
Tg 0.294 -0.046 0.575 0.364 -0.086 0.693 -
TPO 0.716 0.501 0.848 0.722 0.418 0.882 -
Cardiolipin 0.683 0.456 0.830 0.540 0.026 0.782 smoking
SCL-70 0.562 0.284 0.758 0.242 -0.161 0.622 smoking  
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TABLE 4 Path Models for Continuous Antibody Values
Antibody Model A D C E -2log likelihood df p value
Cardiolipin CE 0.67 0.33 2.53 4 0.28
dsDNA AE 0.55 0.44 0.77 4 0.68
Jo-1 DE 0.41 0.59 0.46 4 0.79
Sm non-convergent
Ro(SSA) non-convergent
La(SSB) non-convergent
Sn/RNP non-convergent
SCL-70 AE 0.42 0.58 0.01 4 0.99
PS DE 0.52 0.48 0.78 4 0.68
Tg non-convergent
TPO CE 0.61 0.39 1.27 4 0.53  
TABLE 5
Heritability Estimates of Continuous Antibody Values
Outcome Most Parsimonious Model full ACE full ADE
Cardiolipin 0% 30% 72%
dsDNA 55% 29% 55%
Jo-1 41% 38% 41%
Sm
Ro(SSA)
La(SSB)
Sn/RNP
SCL-70 42% 38% 42%
PS 52% 50% 52%
Tg
TPO 0% 25% 66%  
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TABLE 6 Path Models for Ranked Autoantibody Values
Antibody Model A D C E -2log likelihood df p value
Cardiolipin AE 0.68 0.31 0.60 4 0.74
dsDNA AE 0.61 0.38 0.08 4 0.96
Jo-1 AE 0.51 0.49 0.22 4 0.90
Sm CE 0.64 0.36 0.72 4 0.70
Ro(SSA) CE 0.44 0.56 0.03 4 0.98
La(SSB) non-convergent
Sn/RNP CE 0.69 0.31 0.42 4 0.81
SCL-70 AE 0.59 0.41 0.05 4 0.98
PS DE 0.54 0.47 0.51 4 0.77
Tg non-convergent
TPO non-convergent
 
TABLE 7
Heritability Estimates of Ranked Autoantibody Values
Outcome Most Parsimonious Model full ACE full ADE
Cardiolipin 69% 48% 68%
dsDNA 61% 53% 61%
Jo-1 51% 36% 51%
Sm 0% 18% 67%
Ro(SSA) 0% 5% 48%
La(SSB)
SnRNP 0% 12% 69%
SCL-70 59% 52% 59%
PS 54% 51% 54%
Tg
TPO
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FIGURE 1
Concordance Rates by Antibody
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CHAPTER 4 DISCUSSION 
 
 
This study investigated the heritability of eleven autoantibodies.  Five antibodies 
demonstrated a genetic component in our study population of monozygous and dizygous 
twin pairs.  Heritability estimates were 69% for anti-cardiolipin, 55-62% for anti-dsDNA, 
41-51% for anti-Jo-1, 42-59% for anti-SCL-70, and 52-54% for anti-phospholid.   
The most parsimonious path models for anti-cardiolipin using the ranked values 
included an additive genetic component.  This finding expands on the partial genetic 
determination for anti-cardiolipin found in a previous study44.  The study by Hunnangkul 
et al examined a cohort of families affected by SLE (n=1,037) and found significant 
associations in anti-cardiolipin values between siblings.  Our study found significant 
differences in intraclass correlation differences between monozygous and dizygous twins 
for anti-cardiolipin values.  This significant difference supports the hypothesis of a genetic 
component for anti-cardiolipin values with an estimated heritability for anti-cardiolipin 
expression of 69%. 
The most parsimonious path model for anti-dsDNA using both continuous and 
ranked values included an additive genetic component.  Studies examining anti-dsDNA are 
mixed.  A study examining the genetic contributions to the autoantibody profile in a rabbit 
model of SLE found higher levels of anti-dsDNA among some full siblings and the 
presence of higher immune responder ancestors in their pedigrees 45.  Puliyath et al’s 
findings suggest an additive mode of inheritance with high heritability.  However, Niewold 
  30
et al, found anti-dsDNA to be associated with high interferon alpha levels in SLE patients, 
interferon alpha to be a complex heritable trait, and anti-dsDNA to be rare in healthy 
family members46.  The findings of the present study parallel Puliyath et al’s results by 
finding intraclass correlation suggestive of a genetic effect, path models suggesting 
additive genetic components, and  heritability estimates of 55% and 62% by continuous 
and ranked analysis, respectively. 
Path modeling of anti-Jo-1 suggested a dominant genetic component using 
continuous data and an additive genetic component using categorical data.  This study 
estimated the broad sense heritability to be 41% and 51% by continuous and ranked 
analysis, respectively.  Furthermore, the study found intraclass correlation to be suggestive 
of a genetic component in the continuous data.  O’Hanlon et al determined certain genetic 
markers to be associated with anti-Jo-1 antibodies47.  Although the literature is limited on 
anti-Jo-1 heritability, the O’Hanlon et al study provides evidence that anti-Jo-1 may have a 
genetic component.  Further studies on anti-Jo-1 heritability should be conducted on other 
populations to validate our findings.   
Both continuous and ranked values of anti-SCL-70 had similar results.  The most 
parsimonious path models included an additive genetic component.  The broad sense 
heritability was 42% and 59%, for continuous and ranked values, respectively.  
Additionally, the intraclass correlations suggested a genetic component.  The literature 
supports the finding in this study of a genetic component of anti-SCL-7048.  Takehara et al, 
examined anti-nuclear antibodies in the relatives (n=35) of patients (n=21) with systemic 
sclerosis.  The frequency of anti-nuclear antibodies reported in relatives was 26% and anti-
  31
SCL-70 was detected in the mother of a systemic sclerosis subject.  Although the literature 
is limited and examines only a small population, it supports our findings of a genetic 
component of anti-SCL-70.   
The continuous and ranked values of anti-PS had comparable results.  The most 
parsimonious path models included dominant genetic components.  The broad sense 
heritability was 52% and 54%, for continuous and ranked values, respectively.  
Furthermore, the intraclass correlations suggested a genetic component.  The literature 
supports the findings of this study by providing evidence of linkage for anti-PS to 
chromosome 13q1449.   
Several antibodies did not have a measurable genetic component.  These included 
anti-Sm, anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO.   Path analysis 
of the ranked anti-Sm, anti-Ro(SSA), and anti-sn/RNP values indicated the best fitting 
model had no genetic component.  The covariance matrices of anti-La(SSB), anti-Tg, and 
anti-TPO did not fit the assumptions of the path models and consequently the models were 
non-convergent.  The anti-Tg values had 100% categorical concordance for both 
monozygous and dizygous twins and this lack of discordance minimized the potential for 
meaningful analysis.  The intraclass correlations for anti-Sm, anti-Ro(SSA), anti-La(SSB), 
anti-sn/RNP, anti-Tg, and anti-TPO implied that there is not a genetic component 
detectable in our sample.   
 The literature contains several studies which suggest the possibility of a genetic 
component for anti-Sm, anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO.   
Puliyath et al, in a rabbit model of SLE found genetic contributions to the autoantibody 
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profile of anti-Sm45.  A study of familial aggregation and linkage analysis of autoantibody 
traits in pedigrees for SLE reported evidence for linkage to anti-Sm on chromosome 
3q2749.  Ferreira et al, found IgM anti-Ro to have a uniquely high degree of heritability in a 
study of SLE families50.  A study of familial aggregation and linkage analysis of 
autoantibody traits in pedigrees for SLE found potential evidence for linkage to anti-
Ro(SSA) or anti-La(SSB) on chromosome 4q34-q3549.  Several studies have found nuclear 
antibodies to be associated between relatives45, 48.  The linkage study by Ramos et al, also 
reported evidence that anti-sn/RNP linkage may be associated with chromosome 3q2149.  
Complex segregation analysis in a population of Amish families suggested that 
transmission of anti-TPO is consistent with a mixed model with a major gene transmitted 
in an autosomal dominant pattern51.  Outschoorn et al demonstrated that anti-Tg and anti-
TPO exhibited positive heritability in patients with Graves disease, but not in chronic 
lymphocytic or Hashimoto’s thyroiditis patients52, 53  As the literature suggests, anti-Sm, 
anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO production are likely 
genetically complex traits, however, we did not find a significant genetic component for 
any of these antibodies in our twin population.     
The differences between findings in the literature and the present study may be due 
to the limited number of discordant twin pairs and/or the small number subjects with 
higher levels of auto-antibodies.  This study was limited primarily by the rarity of elevated 
auto-antibody levels in the study population, which resulted in two specific complications.  
The first was that the distributions for the antibody values tended to be skewed rather than 
bimodal.  Since there were relatively few subjects with elevated values, the distribution 
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presented as normal with a few outliers, skewing the data to the maximum.  If there had 
been more subjects with higher antibody values, the outliers would likely have created a 
second normal distribution.  The options to examine data that exhibited a skewed 
distribution include categorizing, excluding outliers, adjustment (i.e. logarithmic or 
exponential), or ranking.  We chose to rank the antibody values so that we would maintain 
the full distribution of the data but minimize the range and variance.   
 The second complication that arises from a lack of subjects with elevated antibody 
values is the inherent lack of statistical power.  The lack of power probably led to the 
inability to detect the presence of genetic components of several of the antibodies.  This is 
even more likely for the antibodies which had strong literature support for a genetic 
component. 
 Several of the studies reported in the literature examined linkage and associated 
antibodies with certain regions of chromosomes.  There is a possible explanation of the 
discordant findings between the linkage studies and our results.  The linkage studies 
examined a diseased population (i.e. SLE) with a potentially rare genetic variation that did 
not occur in our population.  Without this genetic variation, it may be possible to lose the 
genetic component of the autoantibody expression.   
Another point to consider is the entitiy being measured.  The autoantibody assays 
evaluate the presence of autoantibodies, not the likelihood of expressing these antibodies.  
A genetic component may predispose an individual to create an auto-antibody, however, 
unless we are dealing with a purely genetic effect, expression of these antibodies may not 
occur in the absence of an environmental trigger.  Since these samples were taken from 
  34
twins at one point in time, we are limited to the environmental effects present at that 
moment.  It is possible that different phenotypic expressions of antibodies may occur at 
various points in time. 
 A second measurement issue relates to the precision, sensitivity, and specificity of 
the ELISA assays used to quantify the autoantibody values.  The majority of antibody 
values are near zero, leading to the potential of false positives.  Tan et al, examined the 
precision, sensitivity, and specificities of several commercial enzyme based immunoassays 
for the detection of anti-nuclear auto antibodies54.  They found the most evident lack of 
sensitivity and specificity in the anti-dsDNA and anti-Sm kits.   Anti-Ro(SSA), anti-
RoSSB, anti-SCL-70, anti-Jo-1 kits generally perform well.  Several false positives were 
observed in sera containing multiple myeloma cryoprecipitates.  The replicate precision 
had a wide variability between manufacturers.  The results of this precision, sensitivity, 
and specificity analysis suggests a possible source of variability in the auto-antibody 
values and, hence, the entire heritability analysis. 
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CHAPTER 5 CONCLUSION 
 
 
 This study aimed to determine what portion of specific autoantibody 
phenotypes are genetically determined by using a twin model.  This study specifically 
examined Anti-Ro(SSA) antibodies, Anti-La (SSB) antibodies, Anti-Sn/RNP, Anti-Sm 
antibodies, Anti-Jo-1 antibody, Anti-Scl-70 antibody, Anti-Tg & Anti-TPO antibodies, 
Anti-dsDNA antibody, Anti-PS antibodies, and Anti-cardiolipin antibodies for their 
heritability.   
Several antibodies demonstrated a genetic component in our study population.  
Anti-cardiolipin had a genetic component with an estimated 69% heritability.  Heritability 
estimates were 55-62% for anti-dsDNA, 41-51% for Anti-Jo-1, 42-59% for anti-SCL-70, 
and 52-54% for anti-PL.  
Several antibodies did not have a measurable genetic component.  These included 
anti-Sm, anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO.  Possibilities 
for the lack of a measureable genetic component include the limited number of discordant 
twin pairs, and/or the small number subjects with higher levels of antibodies.   
The results of this study suggest several clinically relevant markers of auto-
immunity may be partially genetically determined.  These include:  anti-cardiolipin, anti-
dsDNA, anti-Jo-1, anti-SCL-70, and anti-PL.  These findings provide a basis for 
understanding the mechanisms involved in the various autoimmune diseases associated 
  36
with these autoantibodies.  Additionally, the presence of a genetic component provides a 
new paradigm for possible therapeutics for autoimmune diseases.
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